T. Rowe Price Investment Management, Inc. Ionis Pharmaceuticals Inc Transaction History

T. Rowe Price Investment Management, Inc.

$166 Billion
Q3 2024

A detailed history of T. Rowe Price Investment Management, Inc. transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 14,168,116 shares of IONS stock, worth $482 Million. This represents 0.34% of its overall portfolio holdings.

Number of Shares

14,168,116

Previous 12,639,684 12.09%

Holding current value

$482 Million

Previous $602 Million 5.78%

% of portfolio

0.34%

Previous 0.38%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$40.06 - $51.86 $61.2 Million - $79.3 Million	1,528,432 Added 12.09%	14,168,116 $568 Million
Q2 2024 Aug 14, 2024	SELL	$36.45 - $47.7 $24.7 Million - $32.3 Million	-677,428 Reduced 5.09%	12,639,684 $602 Million
Q1 2024 May 15, 2024	BUY	$42.03 - $53.55 $4.86 Million - $6.19 Million	115,659 Added 0.88%	13,317,112 $577 Million
Q4 2023 Feb 14, 2024	BUY	$43.39 - $51.63 $3.4 Million - $4.05 Million	78,398 Added 0.6%	13,201,453 $668 Million
Q3 2023 Nov 14, 2023	BUY	$38.5 - $47.13 $1.51 Million - $1.85 Million	39,328 Added 0.3%	13,123,055 $595 Million
Q2 2023 Aug 14, 2023	BUY	$34.73 - $43.33 $683,486 - $852,734	19,680 Added 0.15%	13,083,727 $537 Million
Q1 2023 May 15, 2023	BUY	$33.58 - $41.2 $46.5 Million - $57.1 Million	1,385,788 Added 11.87%	13,064,047 $467 Million
Q4 2022 Feb 14, 2023	BUY	$37.12 - $46.52 $19.4 Million - $24.3 Million	521,564 Added 4.67%	11,678,259 $441 Million
Q3 2022 Nov 14, 2022	BUY	$36.54 - $48.66 $408 Million - $543 Million	11,156,695 New	11,156,695 $493 Million

Others Institutions Holding IONS

# of Institutions

402

Shares Held

136M

Call Options Held

862K

Put Options Held

582K

View Full List

About IONIS PHARMACEUTICALS INC

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $4.83B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

More about IONS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of T. Rowe Price Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on T. Rowe Price Investment Management, Inc. with notifications on news.

Account

T. Rowe Price Investment Management, Inc. Ionis Pharmaceuticals Inc Transaction History